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Cephalosporin-resistant Neisseria gonorrhoeae is a major 
public health concern. N. gonorrhoeae of multiantigen se-
quence type G1407 and multilocus sequence type 1901 is 
an internationally spreading cephalosporin-resistant clone. 
We detected 4 cases of infection with this clone in China 
and analyzed resistance determinants by using N. gonor-
rhoeae sequence typing for antimicrobial resistance.
Gonorrhea, the second most prevalent sexually trans-mitted infection (STI) globally, remains a major 
public health concern in China. From 2015 to 2016, the 
reported cases of gonorrhea in China increased by 14.7% 
(100,245 to 115,024) (1). The extended-spectrum cepha-
losporin ceftriaxone has been recommended as mono-
therapy to treat gonorrhea in China since 2007 (2), but 
resistance to this drug emerged almost at the same time 
(3). Presently, the transmission of internationally spread 
cephalosporin-resistant clones in China has become a 
threat to effectively controlling gonorrhea (4). Strains 
with N. gonorrhoeae multiantigen sequence type (NG-
MAST) G1407 and multilocus sequence type (MLST) 
1901 have been successful clones associated with cepha-
losporin resistance and have caused clinical treatment 
failures in France and Spain (5,6); these strains have also 
became the predominant clones in the United Kingdom 
(7) and Japan (8) and among US men who have sex with 
men (9). Here we report 4 cephalosporin-resistant NG-
MAST G1407/MLST 1901 clones identified out of 2,038 
isolates collected through China’s Gonococcal Resistance 
Surveillance Program during 2015–2016.
Demographic and clinical information for the 4 case-
patients are summarized in online Technical Appendix 
Table 1 (https://wwwnc.cdc.gov/EID/article/24/4/17-1817-
Techapp1.xlsx). All case-patients were adult men; gonococ-
cal isolates were obtained from urethral swab samples. The 
4 men had obvious urethral discharge and were diagnosed 
with acute urethritis. Gram staining and culture of the ure-
thral swabs were positive for gonococcal infection. One of 
the 4 patients self-reported being a man who has sex with 
men. One of the infections, occurring in Zhejiang Province, 
was treated with a single-dose regimen of spectinomycin (4 
g); the other 3 infections, occurring in the municipality of 
Chongqing, were treated with a 2-dose regimen of ceftriax-
one (1 g) administered over 2 days. Test-of-cure follow-ups 
were not performed.
All strains were transferred to the reference laboratory 
at the National Center for Sexually Transmitted Disease 
Control, Chinese Center for Disease Control and Preven-
tion. Gram staining, a rapid oxidase reaction test, and a 
carbohydrate utilization test confirmed the identification 
of N. gonorrhoeae. We determined antimicrobial suscepti-
bility to ceftriaxone (CRO), cefixime (CFM), spectinomy-
cin (SPT), azithromycin (AZM), ciprofloxacin (CIP), and 
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penicillin (PEN) by using the agar dilution method. We 
detected β-lactamase (penicillinase)–producing N. gonor-
rhoeae isolates by using a nitrocefin solution filter paper 
test. These strains were resistant to CRO, CFM, PEN, and 
CIP but susceptible to AZM and SPT based on susceptibil-
ity and resistance breakpoints from the European Commit-
tee on Antimicrobial Susceptibility Testing (http://www.
eucast.org/clinical_breakpoints) (Table). MICs of ceftriax-
one ranged from 0.25 to 0.50 mg/L, and MICs of cefixime 
ranged from 0.5 to 1.0 mg/L.
We performed NG-MAST and MLST genotyping to 
identify the sequence types (10). MLST showed all 4 strains 
to be type 1901, and NG-MAST showed the Zhejiang strain 
to be sequence type (ST) 10332 and the Chongqing strains 
to be ST1407. ST10332 has a 2-basepair difference in the 
porB (porB6067) gene from that of ST1407 (porB908) and 
belongs to genogroup G1407. We used N. gonorrhoeae se-
quence typing for antimicrobial resistance (NG-STAR) to 
identify the characteristics of resistance determinants (11). 
NG-STAR showed 2 of the Chongqing strains to be ST90; 
the third Chongqing strain was ST194. The strain isolated 
in Zhejiang was ST507. All 4 strains had type XXXIV mo-
saic penA (penA 34.001), –35A Del in the mtrR promoter 
(mtrR1), G120K-A121N/D in PorB (PorB8/11), L421P in 
PonA (PonA1), S91F-D95A/G in GyrA (GyrA1/7), S87R 
in ParC (ParC3), and wild-type 23srRNA (23 srRNA0) 
(online Technical Appendix Table 2).
We conclude that the internationally reported cepha-
losporin-resistant NG-MAST G1407/MLST 1901 N. gon-
orrhoeae clone has spread into China. Genotyping and 
resistance determinants analysis showed similarity to the 
predominant G1407/MLST 1901 clone reported in other 
regions (7–9), indicating that importation into and trans-
mission within China has occurred. Our findings suggest 
that increased monitoring of this clone by China’s Gono-
coccal Resistance Surveillance Program will be vital for 
monitoring trends in antimicrobial resistance.
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G1407/MLST 1901 infections identified through the national Gonococcal Resistance Surveillance Program, China, 2015–2016* 
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We report an HIV-infected person who was treated for lym-
phogranuloma venereum cervical lymphadenopathy and 
proctitis in Croatia in 2014. Infection with a variant L2b gen-
ovar of Chlamydia trachomatis was detected in a cervical 
lymph node aspirate. A prolonged course of doxycycline 
was required to cure the infection.
Lymphogranuloma venereum (LGV) is a sexually trans-mitted infection caused by serovars L1, L2, and L3 of 
the bacterium Chlamydia trachomatis. The infection typi-
cally causes genital ulcers, proctitis, or femoral/inguinal 
lymphadenopathy with or without constitutional symp-
toms. In the past decade, outbreaks of LGV have been re-
ported in North America, Australia, and Europe, mainly as 
proctitis among HIV-infected men who have sex with men 
(MSM) (1). We report a patient with pharyngitis, proctitis, 
and cervical lymphadenitis in whom LGV-specific DNA 
was detected by real-time reverse transcription PCR (RT-
PCR) in a cervical lymph node fine-needle aspirate.
The patient was a 48-year-old, HIV-positive man in 
Croatia who came to an outpatient HIV clinic in August 
2014 with perianal pain for 10 days and bloody rectal dis-
charge with normal stool consistency. He also reported a 
painful, enlarged cervical lymph node but did not have a 
sore throat. On the first day of the illness, he had fever, 
which subsided the next day. He reported having unpro-
tected receptive anal and oral sex with other men while 
visiting Berlin, Germany, 2 weeks earlier. Clinical exami-
nation demonstrated exudate on the right tonsil, a painful 
and enlarged right cervical lymph node (5 × 2 cm) (online 
Technical Appendix Figure, https://wwwnc.cdc.gov/EID/
article/24/4/17-1872-Techapp1.pdf), perianal pain on pal-
pation, and a purulent rectal discharge.
The patient was given a diagnosis of HIV infection in 
2002 and had been receiving antiretroviral therapy since 
July 2002. Plasma viremia had been undetectable since 
October 2002, and his CD4+ T-cell count before this ill-
ness was 2,082 cells/mm3. His clinical history included 
treatment for neurosyphilis, epilepsy, and diarrhea caused 
by Microsporidiae spp., Blastocystis hominis, and Ent-
amoeba histolytica.
During examination at the HIV clinic, specimens were 
obtained from the pharynx, rectum, and urine for culture 
and a nucleic acid amplification test (NAAT). During fine-
needle aspiration of a cervical lymph node, ≈1 mL of pus 
was removed and analyzed. The lymph node aspirate and 
a rectal swab specimen were positive for C. trachomatis 
DNA by the C. trachomatis/Neisseria gonorrhoeae RT-
PCR (Abbott Laboratories, Abbott Park, IL, USA).
Cytologic examination of the fine-needle aspirate of 
the affected lymph node predominantly showed elements of 
granulomatous inflammation. An indirect immunofluores-
cence assay serum test result for C. trachomatis antibodies 
was positive (IgG titer >1:512, IgA titer 1:256). Test results 
for N. gonorrhoeae were negative (culture of the rectal swab 
and NAAT for urine and rectum). Results of a throat culture 
for Streptococcus pyogenes and routine lymph node aspirate 
culture for bacteria were also negative. Serum serologic test 
results were negative for acute infection with Treponema 
pallidum, Bartonella spp., and Toxoplasma gondii.
1Results from this study were presented as a poster at the 
IDWEEK 2017 Conference, October 4–8, 2017, San Diego, CA, 
USA. Abstracts of the IDWEEK 2017 Conference have been 
published in a supplement issue of Open Forum Infectious 
Diseases (https://idsa.confex.com/idsa/2017/webprogram/
POSTER.html).
